MIR222 (MicroRNA 222)

Therefore, these findings suggest that miRNAs may serve as predictive biomarkers and potential therapeutic targets in the management of breast cancer.

Additionally, a positive correlation was found between the miR-222-3p and IL-6 levels. The expression of miR-222-3p is significantly up-regulated in pediatric MPP, and shows a correlation with disease severity, suggesting it may be a useful biomarker in the clinical assessment of SMPP.

Overall, these results indicate that the DHRS4-AS1/hsa-miR-222-3p/TMBIM6 axis is involved in the progression of PRAD and may act as a prognostic biomarker. Our results provide a foundation for further experimental validation and potential clinical translation.

Combined miRNA profiling highlights miR-222 and, to a lesser extent miR-155, as consistent indicators of myeloid disease transformation. While further validation in larger and genetically stratified cohorts is warranted, these findings support the potential contribution of miRNA signatures to diagnostic evaluation and risk stratification in MDS and AML, in line with precision hematology approaches.

The remaining limitations are inter-study method variation, poor inter-center validation, and unclear regulatory mechanisms of these miRNAs. An effective roadmap will focus on balanced collection and processing, preset thresholds with external calibration and commutable references, and blind prospective trials integrated into clinical practice with decision curve and health-economic analyses to speed up translation.

Kaplan-Meier survival analysis demonstrated that high expression of hsa-miR-15a (p=0.023) and hsa-miR-221 (p=0.048) significantly correlated with poorer overall survival, suggesting their potential prognostic values. Dysregulated expression of cell-cycle-related miRNAs, particularly hsa-miR-15a and hsa-miR-221, may contribute to CESC progression and serve as potential prognostic biomarkers.

Our NGS-based analysis revealed a distinct miRNA expression signature that differentiates prostate cancer from BPH. The downregulation of several tumor-suppressive miRNAs (with concomitant upregulation of oncogenic miRNAs) in prostate cancer may contribute to malignancy-including the de-repression of novel targets like VAPB, which we identify as a promising new biomarker and therapeutic target.

In the training and validation sets, the area under the curve of the 4-miRNA panel was 0.909 and 0.942, respectively. These findings suggest that the serum glycosylated exosomal 4-miRNA panel developed using the GlyExo-Capture approach may serve as a promising strategy for liquid biopsy-based early detection of LUAD.

The proposed logic gate biosensor could not only perform accurate analysis of target cancer cells with high discrimination ratio from normal cells, but also enable visualized detection of miR-222 expression differences in different cancer cell types. This strategy will promote the development of simple and effective biosensors and provide a potential tool for cancer diagnosis and the related biomedical application.

Through computational analysis, we delineate the non-linear decision boundaries that govern melanoma cell fate transitions, taking into account the dynamics of Notch signaling and the role of epigenetic modifications. Our approach highlights the critical interplay between Notch signaling pathways and epigenetic regulation in dictating the fate of melanoma cells. .

Genetic deletion of RASH3D19 in mutant KRAS-expressing cancer cells exhibits growth retardation in vitro, in vivo and sensitized pancreatic ductal adenocarcinoma and colorectal cancer cells, organoids and xenografts to mutant KRAS inhibitors, suppressing feedback reactivation of RAS pathways. Therapeutic targeting of RASH3D19 is expected to lead to tumour debulking and alleviating resistance to KRAS inhibitors in mutant KRAS-expressing cancers.

Circulating miRNA signatures represent promising non-invasive biomarkers for early PM detection and prognostic stratification, particularly in epithelioid cases. Incorporation of these biomarkers into clinical workflows could pave the way for more personalized treatment strategies and optimize patient selection for surgery.